BMO Capital analyst Gary Nachman maintained a Buy rating on Scholar Rock Holding (NASDAQ:SRRK) Corp on Wednesday, setting a price target of $76, which is approximately 150.58% above the present share price of $30.33.
Nachman expects Scholar Rock Holding Corp to post earnings per share (EPS) of -$0.76 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Scholar Rock Holding, with an average price target of $70.5.
The analysts price targets range from a high of $76 to a low of $65.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $4.71 million and a net profit of -$27.21 million. The company's market cap is $1.04 billion.
According to TipRanks.com, BMO Capital analyst Gary Nachman is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.3% and a 47.69% success rate.
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.